Celgene's Revlimid hits main goal in multiple myeloma trial

07/12/2013 | Reuters

Celgene's Revlimid, or lenalidomide, achieved the primary goal of a late-stage study by significantly improving progression-free survival in patients with newly diagnosed multiple myeloma. The drugmaker plans to file regulatory applications in the U.S., Europe and other markets. Revlimid is already cleared for treatment of mantle cell lymphoma, transfusion-dependent anemia caused by myelodysplastic syndromes, and multiple myeloma as a second-line treatment.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC